10 RNA Therapeutics Companies To Watch In 2019

11 / 11
Silence Therapeutics
Silence Therapeutics

Silence Therapeutics plc (SLN.L) (SLNCF.OB) is focused on developing RNAi-based therapeutics for life-threatening diseases.

The Company’s investigational drugs are based on its proprietary short interfering RNA (siRNA) technology that can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins.

The lead candidate is SLN124, currently in preclinical testing for Beta Thalassaemia and Myelodysplastic syndrome. Initiation of phase Ib study of SLN124 is expected in the second half of 2019.

The Company’s out-licensed program Teprasiran (previously known as QPI-1002) is under a phase III trial for the prevention of acute kidney injury following cardiac surgery. Teprasiran is also under a pivotal phase III study for delayed graft function following kidney transplantation.

The clinical studies are being conducted by Quark Pharmaceuticals and its partner Novartis.
If Teprasiran gets approved, Silence is eligible to receive either approximately 1.5%-4% royalties from Quark plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis.

On December 10, 2018, Silence resolved its patent disputes with Alnylam Pharmaceuticals Inc (ALNY) related to the latter’s RNAi drug Onpattro. Under the terms of the settlement, Alnylam will license patents from Silence and will pay Silence a tiered royalty on net sales of Onpattro in the EU ranging from 0.33 percent to 1.0 percent through 2023.

SLN.L closed Friday’s (Dec.28) trading at 51.00p, down 2.86%.